Kura Oncology Inc
(NAS:KURA)
$
8.86
-0.08 (-0.89%)
Market Cap: 688.99 Mil
Enterprise Value: 250.32 Mil
PE Ratio: 0
PB Ratio: 1.63
GF Score: 29/100 Kura Oncology Inc at Credit Suisse Healthcare Conference (Virtual) Transcript
Nov 09, 2021 / 08:30PM GMT
Release Date Price:
$18.41
(-5.01%)
Tiago Felipe Fauth;dit Suisse AG
CrÃ;Research Division - Research Analyst
© -
All right. Welcome, everyone, to Credit Suisse's 30th Annual Healthcare Conference. I'm Tiago Fauth. I'm a biotech analyst here at Credit Suisse, and we're joined today by Kura Oncology. Troy Wilson, CEO, on the line with us for a fireside chat. Feel free to e-mail me any questions, and I'll try to work those in as we go along.
Questions & Answers
Tiago Felipe Fauth;dit Suisse AG
CrÃ;Research Division - Research Analyst
© -
But as usual, we can start with a brief overview as we head into the end of the year. So Troy, I don't know, can you just kind of give us some of the highlights for 2021 and the current status for Kura Oncology? And we'll work off of that.
Troy Edward Wilson
Kura Oncology, Inc. - Chairman, CEO & President
Sure. Yes, Tiago. Thanks. Thank you to you and your colleagues at Credit Suisse for the invitation. It's always a pleasure to chat with you.
As
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot